Pricing Log in Create free account

Curis, Inc. (CRIS) vs Evogene Ltd. (EVGN)

Curis, Inc. and Evogene Ltd. are both Biotechnology companies. Curis, Inc. and Evogene Ltd. are of similar size ($6.0M and $5.7M). Curis, Inc. grew revenue faster over the last twelve months: −13.4% against −73.6%. Curis, Inc. has the higher net margin (0.00% vs −547.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Curis, Inc. leads on 11 and Evogene Ltd. on 6.

Valuation

Metric CRIS EVGN Biotechnology median
P/E n/m n/m 10.60
P/S 0.20 2.06 9.40
P/B 0.40 0.59 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.29 0.55 0.66
EV/Sales (0.27) (3.58) 9.02
Earnings yield (1,615.91%) (325.00%) (32.88%)
Free cash flow yield (1,649.45%) (315.60%) (23.13%)

Profitability

Metric CRIS EVGN Biotechnology median
Gross margin 99.52% (67.59%) 68.51%
Operating margin 0.00% (851.42%) 0.00%
Net margin 0.00% (547.62%) 0.00%
Free cash flow margin 0.00% (650.63%) 0.00%
Return on equity 455.35% (100.03%) (51.96%)
Return on assets (87.76%) (38.31%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRIS EVGN Biotechnology median
Revenue growth (TTM) (13.43%) (73.63%) 6.76%
EPS growth (last fiscal year) 91.57% 62.63% 29.88%
Revenue growth, 5-year CAGR (2.71%) 29.94% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRIS EVGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.49 3.57 4.97
Net debt to EBITDA 0.91 1.12 1.01

Dividend

Metric CRIS EVGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRIS EVGN Biotechnology median
Market cap 5.67m 5.95m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack